Table 1.
Baseline Characteristics of the Study Population
| Total Randomized Population (N = 202) | Per-Protocol Population (n = 191) | Ticagrelor (n = 94) | Placebo (n = 97) | p Value (Ticagrelor vs. Placebo)∗ | |
|---|---|---|---|---|---|
| Age, yrs | 65.9 ± 8.2 | 65.9 ± 8.3 | 65.5 ± 8.4 | 66.3 ± 8.1 | 0.504 |
| Male | 162 (80) | 152 (80) | 74 (79) | 78 (80) | 0.912 |
| Body mass index, kg/m2 | 29.8 ± 5.2 | 29.7 ± 5.0 | 30.0 ± 5.2 | 29.4 ± 4.9 | 0.413 |
| Medical history | |||||
| History of acute coronary syndrome | 143 (71) | 134 (70) | 65 (69) | 69 (71) | 0.887 |
| Days between ACS and randomization | 821 (620–1,056) | 821 (625–1,037) | 800 (620–970) | 861 (646–1,081) | |
| Percutaneous coronary intervention | 163 (81) | 154 (81) | 75 (80) | 79 (81) | 0.915 |
| Coronary artery bypass grafting | 40 (20) | 38 (20) | 18 (19) | 20 (21) | 0.942 |
| Hypertension | 113 (56) | 105 (55) | 52 (55) | 53 (55) | 1.000 |
| Hypercholesterolemia | 195 (97) | 185 (97) | 93 (99) | 92 (95) | 0.228 |
| Diabetes mellitus | 39 (19) | 36 (19) | 19 (20) | 17 (18) | 0.772 |
| Previous stroke/transient ischemic attack | 4 (2) | 4 (2) | 2 (2) | 2 (2) | 1.000 |
| History of atrial fibrillation | 5 (2) | 5 (3) | 4 (4) | 1 (1) | 0.346 |
| Peripheral vascular disease | 8 (4) | 7 (4) | 1 (1) | 6 (6) | 0.134 |
| Medications | |||||
| Aspirin | 202 (100) | 191 (100) | 94 (100) | 97 (100) | NA |
| Statin | 192 (95) | 182 (95) | 92 (98) | 90 (93) | 0.188 |
| Beta-blocker | 138 (68) | 130 (68) | 66 (70) | 64 (66) | 0.637 |
| Angiotensin-converting enzyme inhibitor/angiotensin II receptor blocker | 155 (77) | 145 (76) | 68 (72) | 77 (79) | 0.333 |
| Hemoglobin, g/dl | 14.0 ± 1.3 | 14.0 ± 1.3 | 14.2 ± 1.2 | 13.8 ± 1.3 | 0.034 |
| Estimated glomerular filtration rate, ml/min/1.73 m2 | 0.547 | ||||
| 31–60 | 23 (11) | 22 (12) | 9 (10) | 13 (13) | |
| >60 | 179 (89) | 169 (88) | 85 (90) | 84 (87) | |
| Total cholesterol, mg/dl | 162 ± 39 | 162 ± 39 | 162 ± 39 | 162 ± 35 | 0.852 |
| High-density lipoprotein, mg/dl | 46 ± 12 | 46 ± 12 | 43 ± 15 | 46 ± 12 | 0.128 |
| Low-density lipoprotein, mg/dl | 89 ± 31 | 89 ± 31 | 85 ± 35 | 89 ± 27 | 0.377 |
| Triglycerides, mg/dl | 159 ± 97 | 151 ± 97 | 159 ± 106 | 151 ± 80 | 0.556 |
Values are mean ± SD, n (%), or median (interquartile range).
ACS = acute coronary syndromes.
∗
Post-hoc analysis.